Alnylam Pharmaceuticals has scored an approval from the European Commission for its RNAi therapeutic Oxlumo, for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Alnylam Pharmaceuticals announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) ...